Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57: 1333–1342. doi: 10.1002/hep.26141. pmid:23172780
[2]
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128. doi: 10.1016/S0140-6736(12)61728-0. pmid:23245604
[3]
Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard et al. Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C. Annals Int Med. 2008;149: 399–403. pmid:18794559 doi: 10.7326/0003-4819-149-6-200809160-00006
[4]
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, et al. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. New Engl J Med. 2009;361: 580–93. doi: 10.1056/NEJMoa0808010. pmid:19625712
[5]
Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59:2083–91. doi: 10.1002/hep.27113. pmid:24604476
[6]
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384:1597–605. doi: 10.1016/S0140-6736(14)61059-X. pmid:25078304
[7]
Wyles D, Ruane P, Sulkowski M, Dieterich D, Luetkemeyer AF, et al. Daclatasvir in Combination with Sofosbuvir for HIV/HCV Coinfection: ALLY-2 Study. [Abstract 151LB] Conference on Retroviruses and Opportunistic Infections (CROI). February 23–26; Seattle, WA.
[8]
Nelson DR, Cooper JN, Lalezari JP et al. All-oral 12-week treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology 2015;61:1127–35. doi: 10.1002/hep.27726. pmid:25614962
[9]
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, et al. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. New Engl J Med. 2014;370: 211–221. doi: 10.1056/NEJMoa1306218. pmid:24428467
[10]
Harvoni [package insert]. Gilead Sciences, Inc., Foster City, CA; 2014.
[11]
Pak Viekira [package insert]. AbbVie, Inc., North Chicago, IL; 2014.
Sovaldi [package insert]. Gilead Sciences, Inc., Foster City, CA; 2013.
[14]
Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, et al. Sofosbuvir and Ribavirin for Hepatitis C in Patients with HIV Coinfection. JAMA. 2014;312: 353–361. doi: 10.1001/jama.2014.7734. pmid:25038354
[15]
Flamm SL, Everson GT, Charlton M, Denning JM, Arterburn S, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 1–5, 2014; Boston, MA.
[16]
Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. [Abstract 8.] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7–11, 2014; Boston, MA.
[17]
Lo Re V, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014; 160:369–79. doi: 10.7326/M13-1829. pmid:24723077
[18]
Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, et al. Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons. N Engl J Med. 2004;351: 451–9. pmid:15282352 doi: 10.1056/nejmoa032653
[19]
Falkowski O, An HJ, Ianus IA, Chiriboga L, Yee H, West AB, et al. Regeneration of hepa- tocyte “buds” in cirrhosis from intrabiliary stem cells. J Hepatol 2003;39:357–64. pmid:12927921 doi: 10.1016/s0168-8278(03)00309-x
[20]
Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, et al. (2013) Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource. Hepatology 59(1): 318–327. doi: 10.1002/hep.26744. pmid:24115039
[21]
Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012;56(6):1247–1253. doi: 10.1016/j.jhep.2011.12.033. pmid:22326470
[22]
12. Kwo P, Gitlin N, Nahass R, Bernstein D, Rojter S, et al. A phase 3, randomized, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-na？ve and—experienced patients with chornic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. EASL April 2015, Vienna Austria. Abstract LP14.
[23]
Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-na？ve and—experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. EASL April 2015, Vienna Austria. Abstract LP04.
[24]
Svarovskaia ES, Dvory-Sobol H, Doehle B, Gane E, Jacobson IM, et al. L159F and V321A Sofosbuvir Treatment-Emergent HCV NS5B Substitutions. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7–11, 2014; Boston, MA.
[25]
Sarrazin C, Dvory-Sobol H, Svarovskaia E, Doehle B, McCarville JF, et al. Baseline and Post-Baseline Resistance Analyses of Phase 2/3 Studies of Ledipasvir/Sofosbuvir ± RBV. [Abstract 1926] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7–11, 2014; Boston, MA.
[26]
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros P, et al. All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected with HCV Genotype 3: ALLY-3 Phase 3 Study. 24th Conference of the Asian Pacific Association for the Study of Liver Disease (APASL). March 12–15, 2015; Istanbul, Turkey.
[27]
Lawitz E, Flamm S, Yang JC, Pang PS, Zhu Y, et al. Retreatment of Patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. EASL April 2015, Vienna Austria. Abstract O005.
[28]
Rong L, Dahari H, Ribeiro RM, Perelson AS (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2: 30ra32. doi: 10.1126/scitranslmed.3000544. pmid:20445200
[29]
Howe AYM, Long J, Nickle D, Barnard R, Thompson S, et al. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antiviral Res. 2015;113: 71–78. doi: 10.1016/j.antiviral.2014.10.010. pmid:25446895
[30]
Dvory-Sobol H, Wyles D, Ouyang W, Chodavarapu K, McNally J, et al. Long-Term Persistence of HCV NS5A Variants After Treatment with NS5A Inhibitor Ledipasvir. EASL April 2015, Vienna Austria. Abstract O059.
[31]
Fried MW, Forns X, Reau N, Wedemeyer H, Shiffman ML, et al. TURQUIOSE-II: Regimens of ABT-450/r/ombitasvir and Dasabuvir with Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients with Cirrhosis, Regardless of Baseline Characteristics. [Abstract 81] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7–11, 2014; Boston, MA.
[32]
Naggie S, Cooper C, Saag M, Yang J, Stamm L, et al. Ledipasvir/Sofosbuvir for 12 Weeks in Patients Coinfected with HCV and HIV-1. [Abstract 152LB] Conference on Retroviruses and Opportunistic Infections (CROI). February 23–26; Seattle, WA.
